Continuous versus intermittent infusion of β-lactams in patients with sepsis and septic shock: a systematic review and meta-analysis
Open Access
- 26 September 2025
- journal article
- review article
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 25 (1) , 1-26
Abstract
To assess whether continuous infusion of β-lactam antibiotics improves clinical outcomes compared to intermittent infusion in adult patients with sepsis or septic shock. We conducted a systematic review and meta-analysis of randomized controlled trials comparing continuous versus intermittent β-lactam infusion. Databases searched included PubMed, Scopus, Web of Science, and Embase. Risk of bias was assessed using the RoB 2.0 tool, and the certainty of evidence was evaluated using GRADE. Eleven studies involving 9,166 patients were analyzed, comparing continuous versus intermittent infusion of β-lactams in sepsis or septic shock. There was no significant difference in overall mortality (RR 0.94; 95% CI: 0.88–1.01) or ICU mortality (RR 0.94; 95% CI: 0.88–1.01). Continuous infusion was associated with lower hospital mortality (RR 0.92; 95% CI: 0.85–0.99), higher survival at the end of the study (RR 1.04; 95% CI: 1.02–1.07), and higher clinical cure rate (RR 1.42; 95% CI: 1.12–1.80). No significant differences were observed in the length of stay in the ICU (MD 0.75 days; 95% CI: -1.17 to 2.68) or hospital stay (MD -2.51 days; 95% CI: -10.13 to 5.12), or in the adverse events (RR 0.82; 95% CI: 0.60–1.12). Continuous infusion of β-lactams could reduce hospital mortality and increase the clinical cure rate in critically ill patients, although its effect on overall mortality, hospital stay, and adverse events remains uncertain. PROSPERO number: CRD42024613938.Keywords
This publication has 28 references indexed in Scilit:
- Continuous versus intermittent bolus dosing of beta-lactam antibiotics in a South African multi-disciplinary intensive care unit: A randomized controlled trialJournal of Infection, 2025
- Continuous vs Intermittent β-Lactam Antibiotic Infusions in Critically Ill Patients With SepsisJAMA, 2024
- Prolonged vs Intermittent Infusions of β-Lactam Antibiotics in Adults With Sepsis or Septic ShockJAMA, 2024
- Detailed regimens for the prolonged β-lactam infusion therapyJournal of Infection and Chemotherapy, 2024
- Continuous vs Intermittent Meropenem Administration in Critically Ill Patients With SepsisJAMA, 2023
- In silico evaluation of a beta‐lactam dosing guideline among adults with serious infectionsPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2023
- Effect of therapeutic drug monitoring-based dose optimization of piperacillin/tazobactam on sepsis-related organ dysfunction in patients with sepsis: a randomized controlled trialIntensive Care Medicine, 2022
- Higher than standard dosing regimen are needed to achieve optimal antibiotic exposure in critically ill patients with augmented renal clearance receiving piperacillin-tazobactam administered by continuous infusionJournal of Critical Care, 2018
- Beta-Lactam Infusion in Severe Sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsisIntensive Care Medicine, 2016
- First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsisInternational Journal of Antimicrobial Agents, 2010